

PERSONAL INFORMATION**Armando Ialenti**

📍 Via Giovanni Miranda 3, Napoli, 80130, Italy

☎ + 39 081678424 📠 +39 3492254160

✉ ialenti@unina.it

🌐 <https://www.docenti.unina.it/#!/professor>

Sex M | *Date of birth* 10/06/1958 | *Nationality* Italian

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input checked="" type="checkbox"/> Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist
<input type="checkbox"/> Mid-Management Level	<input type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

WORK EXPERIENCE

(2018- today)

FULL PROFESSOR of Pharmacology (05/BIOS-11), Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II

2000-2018 Associate Professor of Pharmacology at the University of Naples Federico II

1994-1999 Research Fellow, Department of Experimental Pharmacology, University of Naples Federico II.

EDUCATION AND TRAINING

(1986-1990)

PhD in Pharmaceutical Science (curriculum Pharmacology and Toxicology) with a thesis entitled "Vasocortin, a new anti-inflammatory protein induced by glucocorticoids" (1990)

Degree in Pharmacy "summa cum laude" (summa cum laude), University of Naples "Federico II", Experimental thesis in Pharmacology (1984)

Job-related skills

Immuno-inflammatory events in cardiovascular diseases. Specific skill in animal experimental models of cardiovascular disease such as atherosclerosis, restenosis and heart failure. Skills in the basic techniques of molecular and cellular biology. Skills in the field of cell cultures.

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s) English, B1/B2

Mentoring activity Supervisor of several Ph.D. students; Supervisor of numerous undergraduate students; Member of the Doctorate of National Interest in RNA Therapeutic and gene therapy.

Teaching activity Pharmacotherapy and Toxicology, degree course in Pharmaceutical Chemistry and Technology, Department of Pharmacy, University of Naples Federico II (average enrolment 60); Toxicology, Specialisation School in Laboratory Animal Science and Medicine, Department of Veterinary Medicine and Animal Production, University of Naples Federico II

Grants 2000* - Legge 41/84 (Regione Campania), "Fattori di trascrizione: nuovi bersagli molecolari nella terapia delle malattie infettive e infiammatorie", 31.000,00 €
2001 - Ministero dell'Università e Ricerca Scientifica e Tecnologica, "Ruolo delle prostaglandine

ciclopentenoniche nel danno vascolare", 65.074,00 €
 2003* - Ministero dell'Università e Ricerca Scientifica e Tecnologica, "Ruolo dell'interleuchina-18 nel danno vascolare: nuovo possibile bersaglio farmacologico nella prevenzione della restenosi.", 43.600,00 €
 2004 - Ministero dell'Università e Ricerca Scientifica e Tecnologica, "Heat shock proteins e rimodellamento vascolare: nuovi bersagli terapeutici per la prevenzione della restenosi", 42.200,00 €
 2006* - Legge 5 Regione Campania, "Sviluppo di nuovi derivati peptidici inibitori dell'attivazione di NF-kB come potenziali agenti farmacologici nel controllo del danno vascolare", 19.000,00 €
 2007* - Contratto di ricerca con ACRAF "Effect of Bindarit on balloon injury in rats", 50.000,00 €
 2007* - Contratto di ricerca con ACRAF "Effect of Bindarit on Neointimal Hyperplasia in Hyperlipidemic Mice", 50.000,00 €
 2007* - Ministero dell'Università e Ricerca Scientifica, "Meccanismi fisiopatologici e possibili bersagli terapeutici nel danno vascolare", 71.628,00 €
 2008* - Contratto di ricerca con ACRAF "Effect of Bindarit on neointimal formation after balloon angioplasty in porcine coronary arteries", 20.000,00€.
 2008* - Contratto di ricerca con ACRAF "Dissecting the effect of bindarit on human coronary artery smooth muscle cells", 30.000,00 €
 2009* - Contratto di ricerca con ACRAF "Further investigation on the effect of bindarit on human coronary artery smooth muscle cells", 20.000,00 €
 2010* - Contratto di ricerca con ACRAF "Effect of bindarit on smooth muscle cells activation", 25.000,00€
 2011* - Contratto di ricerca con ACRAF "Effect of bindarit on smooth muscle cells activation in vivo", 30.000,00€
 2014* - Legge 5 Regione Campania, "Caratterizzazione delle cellule del sistema immunitario in modelli di formazione neointimale indotti in topi ipercolesterolemici", 25.000,00€
 2017* -Contratto di Ricerca con Neilos Science, Research & Innovation "Valutazione dell'attività espettorante e antiinfiammatoria di diverse formulazioni di Cetraria islandica. Importo finanziato 11.000,00 euro.
 2017 Ministero dell'Università e Ricerca Scientifica e Tecnologica, "Inflammation: cause, consequence and therapeutic target in heart failure and related multi-organo dysfunction", 110.000,00 €
 2020 Ministero dell'Università e Ricerca Scientifica, Senotherapy as new horizon in targeting multi-organ damage and functional decline induced by aging, 163.000,00 euro.
 2023 National Center for Gene Therapy and Drugs based on RNA Technology, Spoke 4 (Metabolic and Cardiovascular Diseases), Progetto MORDRED (miRNA antagonists for the prevention and treatment of metabolic diseases)
 * Grants on which Armando Ialenti is PI

Invited presentations

•2nd Joint Meeting of Italian and Hungarian Pharmacological Societies; Budapest, May 14-15, 1990; "*Vasocortin inhibits Ca²⁺ influx and histamine release induced by concanavalin A in rat mast cells*", Acta Physiologica Hungarica, Vol. 75, Suppl. 147-148, 1990.
 7th International Conference on Prostaglandins and Related Compounds; Florence (Italy), May 28-June 1, 1990; "*Anti-inflammatory activity of phospholipase A2 inhibitory nonapeptides (antinflammins)*".
 Second International Meeting on Biology of Nitric Oxide; London (UK), 30th September-2nd October 1991, 1991; "*Modulation of adjuvant arthritis by endogenous nitric oxide*".
 2nd International Meeting on Biology of Nitric Oxide; London (UK), 30th September-2nd October 1991, 1991; "*Modulation of acute inflammation by endogenous nitric oxide*".
 Second International Workshop on Synovitis; Erlangen (Germany), October 17-19, 1991; "*Suppression of adjuvant arthritis by hyaluronic acid*".
 XXVI National Congress of the Italian Pharmacological Society; Napoli (Italy), 29 settembre - 2 ottobre 1992; "*Exogenous nitric oxide induces acute inflammation*", Pharmacol Res, Suppl 1, 258, 1992.
 British Pharmacological Society Meeting; Cambridge, 5th – 7th January, 1993; "*Modulation of adjuvant arthritis by the L-argine-NO pathway*", Br J Pharmacol 108, Proceedings Suppl, 1993.
 XXVIII National Congress of the Italian Pharmacological Society; Bari (Italy), April 30 – May 3, 1997; "*Leucocytes migration in rat carrageenin-induced pleurisy is modulated by nitric oxide*", Pharmacol Res 35, Suppl, 1997.
 XXIX National Congress of the Italian Pharmacological Society; Florence (Italy), June 20-23, 1999; "*Role of transcription factor NF-kB in a rat model of vascular injury*", Pharm Res 39, Suppl, 1999.
 XXX National Congress of the Italian Pharmacological Society; Genoa (Italy), May 30 – June 2, 2001; "*Evaluation of anti-inflammatory activity of novel synthesized peptides from the protein SV-IV*", Pharm Res 43, Suppl A, 2001.
 XXX National Congress of the Italian Pharmacological Society; Genoa (Italy), May 30 – June 2, 2001; "*Role of heat shock factor 1 (HSF)/heat shock protein 72 (hsp72) pathway in rat carrageenin paw edema*", Pharm Res 43, Suppl A, 2001.

15th World Congress of Pharmacology; Beijing (China), July 2-7, 2006; *“Neutralization of IL-18 inhibits injury-induced neointima formation”*, Acta Pharmacologica Sinica 27, Suppl 1, 2006.
 Convegno Presso l’Azienda Farmaceutica Angelini; S. Palomba (Roma), 14 giugno 2007; *“Inflammatory and immune response to vascular damage in vivo”*.
 First International Advisory Board on Bindarit; Rome (Italy), 15 luglio 2008; *“Bindarit in restenosis animal model”*.
 XV Congresso Nazionale della Società Italiana di Ricerche Cardiovascolari (SIRC); Imola, 9-11 ottobre 2008; *“Bindarit, an inhibitor of MCP-1, attenuates neointimal hyperplasia after balloon injury in rats”*.
 34° Congresso Nazionale della Società Italiana di Farmacologia; Rimini (Italia), 14-17 ottobre 2009; *“Bindarit an inhibitor of monocyte chemoattractant protein-1 synthesis, reduces neointimal hyperplasia both in rats and in hypercholesterolemic mice”*.

Awards Award Winner Poster Section , 15th World Congress of Pharmacology, Beijing (China), July 2-7, 2006; Maffia P, Grassia G, Di Meglio P, Carnuccio R, Berrino L, Garside P, Ianaro A, Ialenti A. *“Neutralization of IL-18 inhibits injury-induced neointima formation”*.
 Award Winner Poster Section, XXXVII Congresso Nazionale della Società Italiana di Farmacologia, Napoli, 27-30 Ottobre 2015); E. Caiazza, S. Morello, A. Ialenti and C. Cicala. *“The anti-inflammatory effect of nimesulide is associated to an increased 5'-nucleotidase/CD73 activity, in vivo”*.

ADDITIONAL INFORMATION h-index: 34
 Scientific Impact 4340 total citations
 91 articles in ISI peer-reviewed journals (60% Q1)
 45 articles as first or last author and corresponding author

Relevant publications -The complete list of Publication is available on Scopus ID 7004054303Scopus and on pubmed: <https://pubmed.ncbi.nlm.nih.gov/?term=ialenti+a>

PLACE AND DATE	According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV
Naples, November 14 th , 2024	<p style="text-align: center;">SIGNATURE</p> 